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Abstract: Mesenchymal stromal cells (MSCs) prepared as advanced therapies medicinal products
(ATMPs) have been widely used for the treatment of different diseases. The latest developments
concern the possibility to use MSCs as carrier of molecules, including chemotherapeutic drugs.
Taking advantage of their intrinsic homing feature, MSCs may improve drugs localization in
the disease area. However, for cell therapy applications, a significant number of MSCs loaded
with the drug is required. We here investigate the possibility to produce a large amount of Good
Manufacturing Practice (GMP)-compliant MSCs loaded with the chemotherapeutic drug Paclitaxel
(MSCs-PTX), using a closed bioreactor system. Cells were obtained starting from 13 adipose tissue
lipoaspirates. All samples were characterized in terms of number/viability, morphology, growth
kinetics, and immunophenotype. The ability of MSCs to internalize PTX as well as the antiproliferative
activity of the MSCs-PTX in vitro was also assessed. The results demonstrate that our approach allows
a large scale expansion of cells within a week; the MSCs-PTX, despite a different morphology from
MSCs, displayed the typical features of MSCs in terms of viability, adhesion capacity, and phenotype.
In addition, MSCs showed the ability to internalize PTX and finally to kill cancer cells, inhibiting the
proliferation of tumor lines in vitro. In summary our results demonstrate for the first time that it is
possible to obtain, in a short time, large amounts of MSCs loaded with PTX to be used in clinical trials
for the treatment of patients with oncological diseases.
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1. Introduction
Mesenchymal stromal cells (MSCs) are considered a promising tool for cell therapy in both
regenerative medicine and immune diseases such as Graft-versus-Host Disease (GvHD), Crohn’s
Disease (CD), and Rheumatoid Arthritis (RA) [1]. Until 2016, 493 MSCs-based clinical trials, either
complete or ongoing, appeared in the database of the US National Institutes of Health [2]. Recently MSCs
have been indicated as a potential new important tool for delivering chemotherapeutic drugs. In fact,
it has been reported that MSCs, upon in vitro exposure to very high concentrations of Paclitaxel (PTX)
can uptake significant amounts of the drug, subsequently released at concentrations high enough to
strongly inhibit cancer cell proliferation, when the PTX loaded MSCs (MSCs-PTX) were located nearby.
We previously demonstrated that the uptake of PTX by MSCs occurs without significant signs of cell
toxicity; PTX affects cytoskeleton by promoting microtubule polymerization that induced the mitotic
arrest of the cells. Morphology and sub-cellular organization of MSCs-PTX were similar to that of
MSCs, but an increased number of vacuole-like structures was detected in MSCs-PTX, some of which
were attributable to microvescicles (MV). PTX, upon entering the cells, locates mainly into MV derived
from Golgi apparatus, where it remains until the moment of the PTX release, that would occur by fusion
of MV membrane with cell membrane, permitting the secretion of PTX in the extracellular environment
and the subsequent antitumor activity. Moreover, the potent anticancer activity of MSCs-PTX has
been proven both in vitro and in vivo using different experimental cancer models [3–10]. Clavreul and
coauthors also demonstrated that MSCs are able to uptake Sorafenib (SFN), carry this drug to a brain
tumor via intranasal administration, and release SFN, resulting in a lower levels of tumor angiogenesis.
The mechanisms by which MSCs uptake/release SFN did not seem to cause cell toxicity, because 80%
of MSCs remained viable 7 days after priming with drug. The route by which SFN leaves MSCs is not
completely known, but as for PTX, it seems that SFN locates into MV and drug release seems to be
connected to the secretion of MV through cell membrane [11].
The use of MSCs in cell therapy approaches requires a rapid large-scale expansion of cells under
Good Manufacturing Practice (GMP) rules, to obtain a clinically relevant number. Traditionally, MSCs
preparation for clinical use can present some critical aspects: (a) cell expansion requires the use of a large
number of flasks; (b) long time in incubators installed in cleanroom facilities; (c) extensive manipulation
by the operators with high risk of microbial contamination, and (d) high cost for GMP-compliant
cells preparation.
With cell-based therapies moving towards commercialization and the increase of clinical trials
in late stage development, it is clear that the selection of suitable manufacturing processes is getting
increasingly important [12]. In the last years several expansion technologies to achieve clinical-scale
MSCs manufacture were investigated, including stacked and multi-layered flask systems, as well as
fully automated bioreactors. The use of bioreactors presents many advantages if compared to cell
expansion methods using culture flasks. A bioreactor, being a closed system, increases the safety of the
process, reduces the risk of microbial contamination and the time of MSCs expansion, and finally allows
to obtain a very high number of cells (due to the maximization of the surface area for MSCs growth) in
a very short time. Moreover, the use of closed systems allows advanced therapy medicinal products
(ATMPs) manufacturing in environments with less stringent GMP classification, thereby reducing
production costs. In addition, bioreactors seem to guarantee a good quality of the product, because the
procedure does not alter the phenotypic profile and functional activity of the cells. To note, the change
of the culture methods can introduce modification of the characteristics and functionality of the cell
products, as the properties of the cells may change even upon minor manipulations. Therefore, it is
crucial to verify whether the method used for cell preparation results in a product that is comparable
in terms of identity, safety, and potency [13–17].
On this basis, we here investigated the possibility to efficiently generate a large amount of MSCs
loaded with the chemotherapeutic drug PTX, by using a novel, closed bioreactor system (Quantum Cell
Expansion System, Terumo BCT), designed for automated cell expansion. Results demonstrated, for the
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first time, that our technical approach is efficient in terms of quantity and quality of MSCs-PTX obtained.
We propose our innovative procedure to prepare MSCs-PTX as ATMP for cancer treatment in humans.
2. Materials and Methods
2.1. Sample Collection
Adipose tissue (AT) lipoaspirates were collected, under general anesthesia, from n = 13
healthy volunteer donors undergoing plastic surgery for aesthetic purposes. The mean age was
42.1 (range: 18–66). Samples were collected after signed informed consent of no objection for the use
for research of surgical tissues (otherwise eliminated) in accordance with the Declaration of Helsinki.
The informed consents were obtained prior to tissue collection; the Ethics Commettee of Regione
Lombardia, Institutional Review Board Section of the IRCCS Neurological Institute C. Besta Foundation
approved (Verbal Number 29, 4 May 2016) the design of the study.
Samples were processed within 24 h from surgery.
2.2. MSCs Isolation from Human Adipose Tissue
MSCs from AT lipoaspirates (AT-MSCs) were isolated as follows: the sample was disaggregated
by enzymatic digestion with 200 U/mL of collagenase type I (Life Technologies, Carlsbad, CA, USA),
then was centrifuged (1000× g, 15 min) and the floating fraction and cellular pellet were plated on
150 cm2 flasks (Euroclone, Milano, Italy), 10 mL/flask, and expanded in DMEM low glucose (Euroclone,
Milano, Italy) supplemented with 5% platelet lysate Stemulate (Cook Reagent, Indianapolis, IN, USA)
and 2 mM l-glutamine (Euroclone, Milano, Italy) until a number of at least 20 × 106 at a passage
not exceeding P3. Primary cultures were analyzed for number and viability at each passage, their
population doubling time (PDT), and the expression of the typical MSC markers (CD90, CD73, CD105;
all the monoclonal antibodies were provided from Becton Dickinson, Franklin Lake, NJ, USA), as
described previously [18].
2.3. MSCs Expansion in Quantum Cell Expansion System
The Quantum Cell Expansion System (Terumo BCT, Lakewood, CO, USA) consists of a synthetic
hollow fiber bioreactor (surface area of 2.1 m2) that works in a sterile closed-loop circuit for media and
gas exchange, as described in details by other previous reports [19–21]. Briefly, after priming of the
disposable expansion set (Terumo BCT, Lakewood, CO, USA), the bioreactor was coated overnight
with 5 mg of human fibronectin (Corning Incorporated, Deeside, UK) to promote cell adhesion; a 4 L
media bag was then attached to the appropriate inlet line on the Quantum disposable expansion set.
All disposable bags used were provided by Terumo BCT, Lakewood, CO, USA.
At least 20 × 106 MSCs expanded as described above were seeded in the system at an inlet rate of
25 mL/min, followed by a 24 h phase in which MSCs recirculate and adhere to the support. As cells
are not visible in the hollow fiber, cell growth was estimated according to lactate generation by the
cells in the system. Fresh complete media is added continuously to cells and the inlet rate is adjusted
as required by the rate lactate generation. During the early phase of MSCs expansion the inlet rate
was 0.1 mL/min up to a lactate value of 3 mM, then the inlet rate was increased at 0.2 mL/min up to a
lactate value of 4 mM, 0.4 mL/min up to a lactate value of 5 mM, 0.8 mL/min up to a lactate value of
6 mM, and finally 1.2 mL/min. At the end of the expansion phase the cells were harvested or cultured
for another 24 h for the drug loading phase.
2.4. Drug Loading Phase of MSCs with PTX
The drug loading of MSCs was performed in the bioreactor by priming the cells according
to a procedure standardized in flasks as previously described, with some modifications [3,22,23].
Drug loading phase begin when lactate value increased less than 0.5 mM in 24 h.
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A 4-L complete medium bag, supplemented with PTX at a final concentration of 10 µg/mL (PTX,
TEVA, Milano, Italy, 6 mg/mL) was prepared and connected to the instrument, as described above.
Through the “touch screen” the medium present in the instrument was completely replaced with
medium supplemented with PTX, within 5 min. This phase was followed by the recirculation of the
medium in the Quantum disposable set for 24 h at an inlet rate of 0.1 mL/min. After 24 h MSCs loaded
with PTX were washed with PBS (Euroclone, Milano, Italy) and detached from the expansion set using
recombinant trypsin (TrypLE Select 1X, Thermofisher, Waltham, MA, USA) and eluted in a 500 mL bag
using complete medium.
An aliquot of fresh MSCs-PTX was used to determine cell number, viability by trypan blue
exclusion test, as well as the quantity of PTX loaded by the cells. The MSCs-PTX were frozen in a sterile
solution of NaCl 0.9% (pharmaceutical grade, Fresenius KABI, Lake Zurich, IL, USA) supplemented
with 5% human albumin (pharmaceutical grade) and 10% of Dimethyl Sulfoxide (Cryosure DMSO
GMP grade, Li StarFISH, Milano, Italy), and cryopreserved in 2 mL cryovials at the concentration of
40–45 × 106 live cells per vial, 2 mL/vial, in nitrogen vapors.
A vial of 10 × 106 cells was used to characterize MSCs-PTX after thawing.
Viability of MSCs-PTX, both fresh and after freeze/thawing, was assessed also over time, re-seeding
cells in T25 flasks (three flasks/condition, total six flasks/experiment, n = 3 experiments) and the
MSCs-PTX viability was analyzed after 7, 14, and 21 days. In this period of time medium was changed
every 3 days; the cells had never been detached, due to the loss of their duplication capacity and the
failure to reach confluence.
2.5. Annexin V and PI Staining
MSCs and MSCs-PTX were collected by centrifugation and washed twice with cold PBS.
After careful remove of supernatant, cells were re-suspended in 1× Binding buffer, following
manufacturer’s instruction, at a concentration of 1 × 106 cells/mL, at least 100 µL per sample.
Annexin V antibody and PI (Becton Dickinson, Franklin Lake, NJ, USA) were added to the samples
and incubated for 20 min at room temperature in the dark. After incubation 400 µL of Binding buffer
was added to each tube. Samples were analyzed immediately (within 1 h) by flow cytometry, using
the instrument FACScalibur and the CellQuest Software (Becton Dickinson, Franklin Lake, NJ, USA).
The data were interpreted as follow: Annexin V negative-PI negative populations are healthy cells;
Annexin V positive-PI negative populations represent cells in early apoptosis; Annexin V positive-PI
positive staining indicates necrotic cells (post-apoptotic necrosis or late apoptosis).
2.6. Tumor Cell Line
Human pancreatic adenocarcinoma cell line CFPAC-1 [24,25] was provided by Centro Substrati
Cellulari, ISZLER (Brescia, Italy), the mesothelioma cell line (NCI H2052) [26] was kindly provided
by Prof Roberta Alfieri (Clinical and Experimental Medicine Department, University of Parma, Italy).
CFPAC-1 cells were maintained in complete medium (Iscove modified Dulbecco’s medium IMDM)
supplemented with 10% Fetal Bovine Serum (FBS) by 1:5 weekly dilution, as mesothelioma cell line
was cultured in RPMI 1640 Medium supplemented with 10% FBS, 1% Hepes, and 1% sodium pyruvate.
All reagents were provided by Euroclone, Milano, Italy.
2.7. HPLC Analysis
The presence of PTX in the MSCs was demonstrated by a validated bioanalytical reversed phase
high performance liquid chromatography (HPLC) assay, as previously described [27]. MSCs-PTX lysates
(MSCs-PTX/LYS) were obtained by sonication performed by three cycles of 0.4 s pulse at 30% amplitude
each (Labsonic UBraun, Reichertshausen, Germany), followed by centrifugation at 2500× g for 10 min.
For HPLC analysis MSC lysates (MSCs/LYS) were mixed (1/4 v/v) with ethyl acetate, vortexed for
8 min, and centrifuged. The supernatants were dried under vacuum (Rotavapor R 110, Büchi) and the
residue reconstituted with 7 µL of mobile phase, filtered through 0.2 µm nylon filters (Phenomenex,
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Phenex-NY 4 mm) and an aliquot of 40 µL injected in HPLC. The chromatographic system (Agilent
1100 Series, Agilent Technologies, Inc. Santa Clara, CA, USA) equipped with nucleodur C18 column,
4.6 × 150 mm, 5 µm particle sizes (Macherey-Nagel), was operated at 30 ◦C in isocratic mode using
acetonitrile and 0.1 M Ammonium Acetate (50/50 v/v) as mobile phase that was pumped at rate of
0.7 mL/min, the eluent was monitoring using UV–Visible DAD detector at 238 nm. The retention time
of PTX was 11 min. A calibration curve (10–25–50–100 ng) of PTX in drug-free lysate was prepared and
processed with the samples and used to quantify PTX (y = 1.1809x − 2.9565; R2 = 0.9963). The extraction
recovery of PTX measured in calibration curve was 78%.
2.8. In Vitro Anticancer Activity of MSCs-PTX
To measure the amount of internalized drug, MSCs-PTX were washed twice with Hank’s solution
(HBSS, Euroclone, Milano, Italy) and 3 × 106 cells suspended in 1.5 mL of complete medium. The cells
were lysed as previously described and MSCs-PTX/LYS were tested for their antiproliferative activity on
standard cancer cell line CFPAC-1 in 96 multiwell plates (Sarstedt, Numbrecht, Germany) as previously
described [27,28]. The activity of lysates was compared with that of pure PTX, according to a biological
dosage assay and the lysate obtained from untreated MSCs were used as control. Briefly, 1:2 serial
dilutions of pure drug (PTX), MSCs/LYS, and MSCs-PTX/LYS were performed in 100 µL of culture
medium/well and then 1000 tumor cells were added to each well. The cell growth was evaluated
after 7 days of culture at 37 ◦C and 5% CO2, by measuring the optical density at 550 nm in a MTT
(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazoliumbromide) assay (Sigma-Aldrich, Darmstadt,
Germany) [29]. The inhibitory concentrations (IC50) were determined as µL/well of lysate according
to the Reed and Muench formula [30]. By comparing the IC50 value of lysate with that of pure PTX
(ng/mL) the PTX Equivalent Concentration (PEC) was extrapolated: PEC (ng/mL) = IC50 PTX × 100/V50
(µL/well) where IC50 PTX = the concentration of pure PTX and V50 = the volume of MSCs-PTX/LYS able
to produce a 50% inhibition of cell proliferation. The PEC value was used to calculate the amount of PTX
incorporated by a single MSC (pg/cell) = PEC (ng/mL) × lysate volume (mL) × 1000/number of cells [31].
2.9. Potency Test
Conditioned media from MSCs-PTX (MSCs-PTX/CM) were prepared seeding MSCs-PTX in
48 multiwell plates (24,000 cells/well, 350 µL/well); the plates were maintained at 37 ◦C, 5% CO2,
and Conditioned Media (CM) were collected after 24, 48, 72, 96, 120 h after seeding. The effect of
pure PTX and MSCs-PTX/CM against tumor cell proliferation was studied in 96 multiwell plates
(Sarstedt, Numbrecht, Germany) by using as target pancreatic adenocarcinoma cells (CFPAC-1) and
a mesothelioma cell line (NCI H2052). Briefly, 103 tumor cells were seeded in each well in 100 µL of
culture medium/well and after 24 h MSCs-PTX/CM was added to each well. A serial dilutions curve of
pure drug as well as MSCs-PTX/LYS were plated as controls. After 7 days of culture at 37 ◦C and 5% CO2
cell growth was evaluated by MTT assay (Promega, Medison, WI, USA), as previously described [29].
2.10. Statistical Analysis
Data are expressed as the mean ± SD. For statistical analysis t-test and one-way analysis of variance
(ANOVA) using GraphPad INSTAT program (GraphPad Software Inc., San Diego, CA, USA) and
p values < 0.05 were considered statistically significant. The linearity of response and the correlation
were studied using regression analysis by Excel Software, Version 2007 (Microsoft, Inc., Redmond,
WA, USA).
3. Results
3.1. MSCs Isolation from Human Adipose Tissue
The mean quantity of the 13 lipoaspirate samples was 40.55 ± 11.3 mL (mean ± SD, range from
25 to 60 mL).
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We were able to isolate MSCs from 100% of the samples. MSCs sprouted from the lipoaspirates
after a median time of 3.88 days (range: 3–5 days) and underwent the first detachment (Passage 1,
P1) after a median time of 11.44 days (range: 7–14 days). The cells were expanded in flasks until a
number of at least 20 × 106, as requested in user’s instruction of Quantum Cell Expansion System, at a
maximum passage of P3. The mean number of MSCs obtained after the first expansion was 28.5 × 106
(SD: 3.96 × 106).
The cultured cells displayed the typical spindle-shaped morphology (Figure 1A), with a PDT at
P2 of 34.84 ± 12.07, at P3 of 33.54 ± 4.96 h.
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Figure 1. (A) Mesenchymal stromal cells (MSC) orphology. Spindle-shaped morphology of MSCs
(P3) after the first expansion phase. Magnification 5×. (B) Paclitaxel-loaded Mesenchymal Stromal
Cells (MSCs-PTX) morphology. Round-shaped morphology of MSCs-PTX after expansion and loading
in Quantum cell expansion system. Magnification 5×.
During this culture period, cells maintained a high percentage of viability, as evaluated by trypan
blue exclusion test at every passage; the mean value was 96.04%, (ranging from 93.18% to 99.42%).
Importantly, cell viability was not affected by cryopreservation, as after thawing cells viability was
94.75% (mean), ranging from 92.15% to 98.56%.
The flow cytometry analysis of the cells confirmed the MSCs phenotype (see Section 3.3).
3.2. MSC Expansion and Loading with PTX in Quantum System
A mean of 23.51 × 106 MSCs (SD: 4.43 × 106) were loaded for expansion in the Quantum Cells
Expansion System. The first run of the bioreactor was performed in order to set a standard procedure
for MSCs expansion, without loading cells with PTX; the expansion length from cell loading to the
harvest phase was 6 days. During this period of time lactate value increased from 0.4 to 9.2 mM
reached at the end of the expansion phase. The total number of recovered MSCs was 480 × 106, with a
viability of 94%.
After this preliminary experiment, 12 MSCs preparations ere expanded and directly loaded with
PTX in th bioreactor. After a mean of 6 days from start of expansions (range: 5–8 days), when lactate
mean value was 8.07 mM (range: 5.5–10.3 mM) PTX was added and 24 h later cells were harvested.
A mean of 591.43 × 106 MSCs-PTX (range: 290 × 106–940 × 106 cells) with a mean viability of 94.34%
were obtained. MSCs-PTX were then processed for cryopreservation.
MSCs-PTX viability was not affected by cryopreservation, as the mean viability after thawing was
91.4% (range 88.84%–95.5%); recovery after thawing was 83.35% ± 11.73% (mean ± SD).
Viability values of MSCs-PTX, both fresh and after freeze/thawing, were maintained over time up
to 21 days after re-seeding of cells, as shown in the Supplementary Table S1.
3.3. Phenotypic Profile of MSCs-PTX
The MSCs-PTX recovered after thawing were investigated to verify if PTX treatment could
have altered their phenotypic and functional features. Results indicate that MSCs-PTX maintained
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unchanged adhesion capacity to plastic support and showed an altered morphology, as expected
(Figure 1B); moreover, cells lost the growth capacity.
The change in cell morphology does not seem to be linked to the bioreactor expansion process,
since the same altered morphology also appears after loading MSCs with PTX in flasks (Supplementary
Figure S1).
Only a small percentage of MSCs-PTX displayed necrotic and/or apoptotic features but not
significant differences compared to control untreated MSCs were found: necrotic cells were 9.9% ± 3.6%
vs. 4.83% ± 0.2% (mean ± SD), apoptotic cells were 13.2% ± 11.72% vs. 5.2% ± 5.64% (mean ± SD)
(Figure 2).
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Figure 2. Apoptosis and necrosis. Analysis of apoptotic and necrotic cells performed by flow cytometry
on MSC and MSC-PTX. The percentage of positive cells is reported as the mean± SD of n = 6 experiments.
No statistically significant differences were found (p > 0.2).
Results of the apoptotic and necrotic cell populations detected by Annexin V-FITC and PI staining
of a representative sample of MSCs and the corresponding MSCs-PTX are shown in the Supplementary
Figure S2.
Flow cytometry analysis showed that MSCs, after the first expansion in flasks displayed
high percentages of the typical MSC markers (CD90 = 94.4% ± 8.2%, CD105 = 80.5% ± 15.4%,
and CD73 = 98.5% ± 1.2%) and were negative for hematopoietic markers (CD31 = 2.16% ± 2%,
CD34 = 1.4% ± 1.7%, and CD45 = 11.5% ± 9.3%; these percentages were maintained after large-scale
expansion and loading with PTX in bioreactor (CD90 = 88.3% ± 6%, CD105 = 83.7% ± 14.3%,
CD73 = 98.9% ± 0.7%, CD31 = 1.2% ± 1.6%, CD34 = 3.68% ± 2.3%, and CD45 = 9.4% ± 5.1%) (Figure 3).
Pharmaceutics 2020, 12, x FOR PEER REVIEW 7 of 15 
 
The MSCs-PTX recovered after thawing were investigated to verify if PTX treatment could have 
altered their phenotypic and functional features. Results indicate that MSCs-PTX maintained 
unchanged adhesion capacity to plastic support and showed an altered morphology, as expected 
(Figure 1B); moreover, cells lost the growth capacity. 
The change in cell morphology does not seem to be linked to the bioreactor expansion process, 
since the same altered morphology also appears after loading MSCs with PTX in flasks 
(Supplementary Figure S1). 
Only a small percentage of MSCs-PTX displayed necrotic and/or apoptotic features but not 
significant differences compared to control untreated MSCs were found: necrotic cells were 9.9% ± 
3.6% vs. 4.83% ± 0.2% (mean ± SD), apoptotic cells were 13.2% ± 11.72% vs. 5.2% ± 5.64% (mean ± SD) 
(Figure 2). 
 
Figure 2. Apoptosis and necrosis. Analysis of apoptotic and necrotic cells performed by flow 
cytometry on MSC and MSC-PTX. The percentage of positive cells is reported as the mean ± SD of n = 
6 experiments. No statistically significant differences were found (p > 0.2). 
Results of the apoptotic and necrotic cell populations detected by Annexin V-FITC and PI 
staining of a representative sample of MSCs and the corresponding MSCs-PTX are shown in the 
Supplementary Figure S2. 
Flow cytometry analysis showed that MSCs, after the first expansion in flasks displayed high 
percentages of the typical MSC markers (CD90 = 94.4% ± 8.2%, CD105 = 80.5% ± 15.4%, and CD73 = 
98.5% ± 1.2%) and were negative for hematopoietic markers (CD31 = 2.16% ± 2%, CD34 = 1.4% ± 
1.7%, and CD45 = 11.5% ± 9.3%; these percentages were maintained after large-scale expansion and 
loading with PTX in bioreactor (CD90 = 88.3% ± 6%, CD105 = 83.7% ± 14.3%, CD73 = 98.9% ± 0.7%, 
CD31 = 1.2% ± 1.6%, CD34 = 3.68% ± 2.3%, and CD45 = 9.4% ± 5.1%) (Figure 3). 
 
Figure 3. Flow cytometry analysis. Immunophenotypic characterization was performed by flow 
cytometry on MSC (n = 13) and MSC-PTX (n = 12) after the first expansion phase (pre) and after 
expansion and loading in Quantum cell expansion system (post), respectively. The percentage of 
positive cells is reported as the mean ± SD. No statistically significant differences were found (p > 
0.5). 
l tr . I munophenotypic characterization was perfor ed by fl
t tr 3) - ( 12) after t e first si se ( r )
i l i i t ll i t t , ti l . t
siti lls is reported as the mean ± SD. No statistically significant diff renc s were found (p > 0.5).
In the Supplementary Figure S3 the flow cytometry analysis of a representative MSCs line is
displayed, before (A) and after (B) expansion and loading with PTX in the bioreactor.
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3.4. HPLC Dosage of PTX Incorporated by MSCs
The drug incorporation of PTX by loaded MSCs was confirmed by HPLC analysis performed on
nine samples. As shown by a standard HPLC chromatograms (1.000 ng/mL of PTX) (Figure 4A) the
drug was eluted with a peak at 11 min. A peak with an identical retention time for PTX was eluted
by processing MSCs-PTX/LYS (Figure 4B). HPLC analysis revealed the presence of other non-specific
peaks (at 2.5–4 min) due to compounds produced by cells that do not correlate with the presence of
PTX, these peaks also being present in the chromatogram of MSCs/LYS, used as control (Figure 4C).
Figure 4D represents the standard chromatogram of PTX. The presence of the main PTX metabolite
(6 alpha-hydroxypaclitaxel), normally eluted at 5.5 min, and of other PTX metabolites can be excluded
(p > 0.5) [32].
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The figure reports the chromatogram profiles of one typical determinatio by HPLC analysis of the
PTX incorporated by MSCs. (A) HPLC chromatogra of lysates from MSCs (MSCs Lysates, MSCs/LYS)
plus standard drug (PTX = 1.000 ng/mL). The drug was eluted with a peak at 11 min. (B) HPLC
chromatogra s of MSCs/LYS loaded with PTX (MSCs-PTX/LYS) showing a peak of identical retention
time. HPLC analysis revealed the presence of other nonspecific peaks (at 2.5–4 min) also present in
the chromatogram. (C) HPLC chromatogram of lysate from untreated MSCs/LYS (control). (D) PTX
standard chromatogram.
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3.5. In Vitro Anticancer Activity of MSCs-PTX
The anticancer activity of MSCs-PTX was evaluated by testing their cell lysate on the tumor cell
line CFPAC-1, used as reference cells to validate the antitumor efficacy [33]. The antiproliferative
effect of different dilutions of the cell lysates from cryopreserved MSCs-PTX (MSCs-PTX/LYS-FT),
fresh MSCs-PTX (MSCs-PTX/LYS-F), and untreated MSCs obtained through bioreactor procedure were
compared (Figure 5). Both MSCs-PTX/LYS-F and MSCs-PTX/LYS-FT induced a significant inhibition
of CFPAC-1 proliferation showing a dose–response kinetics that was expressed as percentage of
proliferation normalized on the basal value produced by control lysates, obtained from untreated
MSCs. A significant linear regression slope (p < 0.001) and high coefficient of correlation (R2) were
found (Figure 5A). As reported in Figure 5B,C, the biological dosage performed by comparing the
dose–response inhibition curve of MSCs-PTX with that of pure PTX estimated the PEC values that
indicate the amount of a drug incorporation for single cell, that was 0.094 ± 0.05 pg/cell (mean ± SD)
for MSCs-PTX/LYS-FT and 0.124 ± 0.059 pg/cell (mean ± SD) for MSCs-PTX/LYS-F; the difference was
not statistically significant (p > 0.1). Based on the amount of drug incorporated and carried by each
cell, we estimated that, in order to produce 50% inhibition of CFPAC-1 proliferation, about 1.2 × 104 of
PTX loaded cells were required. The amount of PTX incorporated by MSCs evaluated by the biological
activity on CFPAC-1 was also compared with those evaluated by HPLC analytical method. As shown
in Figure 5C lower activity of the frozen samples correlated with a lower dosage by HPLC. However,
these differences were not statistically significant (p > 0.3).
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Figure 5. Anticancer activity of lysates of MSCs-PTX. (A) The graph shows the anticancer effect of
MSCs-PTX/LYS expressed as percentage of CFPAC-1 proliferation referred to that of untreated tumor
cells (100% proliferation). The linear regression and the correlation coefficient (R2) of the dose response
kinetics is reported. (B,C) The histogram and the table report the PTX Equivalent Concentration
(PEC) values of the drug incorporated by each MSCs (pg/mL) estimated by the biological dosage
assays and by analytical assay HPLC. All the data are expressed as mean ± standard deviation (SD) of
nine experiments. MSCs-PTX/LYS–F: lysates from fresh MSCs-PTX; MSCs-PTX/LYS–FT: lysates from
frozen-thawed MSCs-PTX.
We then evaluated the in vitro antitumor potential of MSCs-PTX derived CM (MSCs-PTX/CM).
Two human cell lines (human pancreatic adenocarcinoma cell line CFPAC-1 and mesothelioma cell line
NCI H2052) were used. As shown in Figure 6 all MSCs-PTX/CM were able to inhibit cell proliferation of
both CFPAC-1 (A) and NCI-H2052 (B). The antiproliferative capacity of MSCs-PTX/CM was equivalent
to those obtained by adding pure PTX ranging from 10.99 ± 3.82 ng/mL to 17.36 ± 4.22 ng/mL for
CFPAC-1 and from 15.14 ± 3.15 ng/mL to 27.35 ± 3.98 ng/mL for NCI-H2052. A high antitumor activity
of MSC-PTX/CM was maintained at 48 and 72 h, decreasing only at 96 h incubation.
Pharmaceutics 2020, 12, 411 10 of 15
Pharmaceutics 2020, 12, x FOR PEER REVIEW 10 of 15 
 
MSCs-PTX/CM was equivalent to those obtained by adding pure PTX ranging from 10.99 ± 3.82 
ng/mL to 17.36 ± 4.22 ng/mL for CFPAC-1 and from 15.14 ± 3.15 ng/mL to 27.35 ± 3.98 ng/mL for 
NCI-H205 . A high antitumor activity of MSC-PTX/CM was maintained at 48 and 72 h, decreasing 
only at 96 h incubation. 
 
Figure 6. Potency. MSCs-PTX-derived Conditioned Medium (MSCs-PTX/CM) antiproliferative 
activity (blue line) on (A) the target pancreatic adenocarcinoma cells CFPAC-1 and (B) the 
mesothelioma cell line NCI H2052. Data are expressed as Paclitaxel Equivalent Concentration (PEC 
ng/mL, y axis). The x axis represents the time of CM collection after starting culture; the percentages 
of inhibition of cell line proliferation (range min–max) are delimited by parentheses (round brackets) 
at each time point. As shown, the antitumor activity of MSC-PTX/CM is already evident at 24 h, 
remained constant at 48 and 72 h, and decreased only at 96 h from initial culture. CM: orange dot 
represents the effect of CM from untreated MSCs (CTRL: control). 
4. Discussion 
As MSCs seem a very promising tool to use for cell therapy [1], the development of a standard 
procedure is fundamental to optimize their preparation, to reduce variability among batches, and to 
attain reproducible ATMPs. Therefore, the development of the most reliable and reproducible 
method for MSCs isolation and expansion is crucial to get adequate quantity of high-quality MSCs 
for cell therapy. 
Previous studies, from our group and others, demonstrated that MSCs, when exposed to a 
significant amount of anticancer drugs, are able to uptake and subsequently release the drugs, thus 
becoming an effective tool to transport and deliver molecules at the tumor site [3,5,6]. 
Among the different drugs used to load MSCs, PTX is a very promising molecule, combining 
both antiproliferative and antiangiogenic activity [8,9]. We demonstrated that PTX after loading is 
released by MSCs both as free molecules and associated to extracellular microvesicles [10,34]. 
Indeed, in order to better investigate the possible morphological alterations induced on MSCs by 
Figure 6. Potency. MSCs-PTX-derived Conditioned Medium (MSCs-PTX/CM) antiproliferative activity
(blue line) on (A) the target pancreatic adenocarcin ma cells CFPAC-1 and (B) the mesothelioma cell
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4. Discussion
As MSCs seem a very promising tool to use for cell therapy [1], the development of a standard
procedure is fundamental to optimize their preparation, to reduce variability among batches, and to
attain reproducible ATMPs. Therefore, the development of the most reliable and reproducible method
for MSCs isolation and expansion is crucial to get adequate quantity of high-quality MSCs for
cell therapy.
Previous studies, from our group and others, demonstrated that MSCs, when exposed to a
significant amount of anticancer drugs, are able to uptake and subsequently release the drugs, thus
becoming an effective tool to transport and deliver molecules at the tumor site [3,5,6].
Among the different drugs used to load MSCs, PTX is a very promising molecule, combining both
antiproliferative and antiangiogenic activity [8,9]. We demonstrated that PTX after loading is released
by MSCs both as free molecules and associated to extracellular microvesicles [10,34]. Indeed, in order
to better investigate the possible morphological alterations induced on MSCs by PTX treatment and the
involvement of MV in PTX delivery, a fine morphological investigation was performed, showing that
morphology and sub-cellular organization of both MSCs and MSCs-PTX were similar, but an increased
number of vacuole-like structures can be detected in MSCs-PTX, some of which were attributable to
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maturing multi-vesicular bodies; variably sized vesicles budding from or lying near the cell surface
were observed. The release was achieved by fusion of MV membrane with cell membrane and exosome
delivery in the extracellular environment. [3,10]. It is correct to consider that in vivo also the cell
death can contribute to deliver drug in situ. Furthermore, it is also possible that the MSCs secretoma
contribute to increase the anticancer action of PTX.
Regarding the in vitro anticancer activity, we found that the capacity to inhibit cancer cells
proliferation either using cell lysate or the conditioned medium (CM) was not different from those
previously reported by our group [3,31]. We know that there is a big difference between cell lysates or
CM and viable cells, indeed we also performed previous studies in vitro by co-culturing MSCs-PTX
(from different sources) and several tumor models [3,22,31], but in this study we preferred to optimize
a potency test that could also be used as quality control test for batch release.
The use of MSCs to transport and delivery anticancer drugs should have several potential
advantages over the free-form drugs: (a) this approach may increase the protection of the drug from
degradation before reaching the target cancer cells; (b) MSCs being capable of integrating into the
tumor stroma, PTX loaded MSC could be important for loco-regional treatment of solid tumors, where
the delivered drug can reach effective anticancer level into the tumor environment thus increasing
tumor drug uptake; (c) drug delivered by the cells can be better localized in the tumor mass by reducing
its interaction with normal cells and contributing to decreasing systemic toxicity, due to the high
dosage needed to inject drugs intravenously, to reach high levels into the tumor mass. On the other
side, free PTX injected in situ is rapidly absorbed in blood, with a low local efficacy. The above points
could explain the effectiveness of the treatment, as demonstrated in some preclinical studies carried
out by our group [7].
It is true that we do not really know what the behavior of MSCs-PTX would be once transplanted
into a host, when transplanted and exposed to the patient’s own biological milieu. Normal unloaded
MSCs can undergo changes that alter their targeting capabilities. Unfortunately, to date, no studies
in humans exist that can give us indications about this issue, nevertheless, our preliminary studies
“in vivo” reassured us, as it does not appear from the data obtained a change in the behavior of
MSCs-PTX transplanted in mice or rats. However, we know that these cells lose their ability to
proliferate and differentiate and in our experiments demonstrated the anticancer-activity of MSCs-PTX
both in vitro and in vivo in many tumor models (i.e., glioblastoma, pancreatic adenocarcinoma,
pulmonary tumors) [3,22,31].
One of the major limitations to translating these results in the clinical practice remains the difficulty
of producing a large amount of MSCs-PTX in a reasonably short period of time. Keeping in mind
that GMP rules has recently recommended the development of closed processes to improve aseptic
conditions, we speculated to use a closed bioreactor system, designed for automated cell expansion, to
efficiently generate large amounts of MSCs loaded with PTX, leading to the possibility of developing a
new ATMP to be used for the therapy of human cancers.
The use of bioreactors to produce clinical-grade MSCs has been already described [35,36], but the
idea to use a bioreactor to develop a new ATMP that combine cells and an anticancer drug, such as
PTX, is, to our knowledge, completely new.
We here describe a successful procedure that leads to producing up to several millions of MSCs-PTX
in very few days. Our procedure starts from an initial injection of MSCs into bioreactor of approximately
20 million, according to previously described reports [35,36]. The initial step of MSCs isolation and
expansion is performed under standard conditions, and this step, according to GMP suggestions, could
be considered a technical limit of the bioreactor. However, we used this isolation/first expansion phase
to select, through the choice among different MSCs preparations, those with the lowest PDT value.
This choice has the advantage that only MSCs preparations with a high proliferative rate, thus those
with a lower number of in vitro culture passages, were used for large-scale expansion in the bioreactor.
To note, a reduction of the number of passages may reduce the risk of potential MSCs modifications,
that can occur during a prolonged culture [37,38].
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Regarding this, Von Bahr and colleagues recently published clinical results suggesting that acute
GvHD patients treated with early passage MSCs had a better survival than those treated with late
passage cells [39]. Indeed, it is now generally accepted that MSCs will begin to senesce after a certain
number of cell divisions and that this is better evaluated by their PDT rather than by the number of
passages or the duration of culture.
We here performed 13 different preparations of MSCs-PTX; we were able to produce at the end of
the production process a mean of 591.43 × 106 MSCs-PTX (range: 290 × 106–940 × 106 cells) in only few
passages, demonstrating that loading MSCs with PTX does not cause a decrease in yield in terms of
large scale cell expansion; indeed other groups, addressed to optimize large scale expansion of MSCs
without loading them with drugs, described that using bioreactors it is possible to obtain a mean of
451 million cells [15,35,36].
The cells obtained through the bioreactor procedure, maintained high levels of the typical MSCs
phenotypic markers (CD105, CD90, CD73) with a very low content of cells with necrotic or apoptotic
features. HPLC analysis confirmed the presence of PTX in the MSCs preparations and, most importantly,
either their lysate or CM were able to strongly inhibit in vitro human cancer cell proliferation. Each lot
resulted very similar in terms of phenotypic features and antitumor activity (meaning also PTX
incorporation), indicating a high level of reproducibility of our preparation method. In our opinion
this result is very important, particularly in light of the effort of many investigators working to reduce
the high variability among ATMP preparations [40].
Finally, it was essential to determine if MSCs-PTX prepared in a bioreactor could be banked in
view of their allogeneic use for patient treatment scheduled over time. We evaluated the possible
banking of MSCs-PTX by investigating if their function was maintained after cryopreservation; results
displayed that the function and the potency, in terms of viability, recovery, and PTX release capacity of
thawed cells did not differ statistically from those of fresh cells.
5. Conclusions
In conclusion the results of our study validate a protocol that is suitable for large scale production
of MSCs loaded with PTX to be used in clinical trials for the treatment of patients with oncological
diseases. Further studies will be addressed to evaluate the time freezing stability of MSCs-PTX (at least
up to 12 months) and to validate the procedure under GMP condition to obtain the authorization by
regulatory agency to produce a cell therapy product to enter a phase I clinical trial in patients with
malignant pleural mesothelioma.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/5/411/s1,
Table S1. MSCs-PTX viability over time. Viability of both fresh and freeze/thawed MSCs-PTX obtained with
bioreactor, assessed after 7, 14 and 21 days from re-seeding in plastic flasks. In this period of time medium was
changed every 3 days; the cells have never been detached, due to the lost of their duplication capacity and the
failure to reach confluence. Results were expressed as mean ± SD of n = 3 experiments. F: fresh, FT: freeze/thawed,
Figure S1. MSCs and MSCs-PTX morfology. (A) MSCs, cultured in plastic flasks (pre-treated with fibronectin;
passage 3); (B) MSCs-PTX cultured in plastic flasks (pre-treated with fibronectin; cells were loaded with PTX at the
end of passage 3 and the image was taken 24 h after); (C) MSCs expanded in bioreactor; (D) MSCs expanded and
loaded with PTX (for 24 h) in bioreactor. Magnification 5×, Figure S2. Flow cytometry analysis of apoptosis and
necrosis. The dot plot diagrams represent typical apoptotic and necrotic cell populations detected by Annexin
V-FITC and PI staining. A) MSCs-PTX; B) MSCs. The lower left quadrants of the panels show viable intact cells
(double negative); the upper right quadrants show necrotic cells (double positive); the lower right quadrants
represents apoptotic cells, positive for Annexin V and negative for PI. Diagrams are representative for one of
6 repeated experiments, Figure S3. Flow cytometry analysis of a representative MSCs line, before and after
expansion and loading with PTX in the bioreactor. (A) analysis of the typical positive MSC markers CD73 (upper
line, left), CD90 (upper line, center) and CD105 (upper line, right) and the negative MSCs markers CD31 (lower
line, left), CD34 (lower line, center) and CD45 (lower line, right); (B) analysis of the correspondent MSCs-PTX for
CD73 (upper line, left), CD90 (upper line, center) and CD105 (upper line, right), CD31(lower line, left), CD34
(lower line, center) and CD45 (lower line, right).
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